Video

Dr. Kuzel on Immunotherapy as a Targeted Approach to Cancer

Timothy M. Kuzel, MD, FACP, discusses the use of immunotherapy as a targeted approach to treating cancer.

Timothy M. Kuzel, MD, FACP, chief, Hematology Oncology and Cell Therapy, Rush University Medical Center, discusses the use of immunotherapy as a targeted approach to treating cancer.

Over the past few years, many new approaches and agents have been developed to treat patients with a variety of cancers, including kidney cancer, melanoma, bladder cancer, and more, according to Kuzel. Compared with previous years, Kuzel believes this year has seen fewer novel drugs and big trials with paradigm shifts; rather, there are more data refining the way these drugs should be used. Kuzel has seen studies examining genetic sequencing and mutations in certain tumors, which has an impact on the response to immunotherapy.

The medical community is starting to think of immunotherapy as a targeted approach to cancer rather than a broad therapeutic approach, according to Kuzel.

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center